John W. White

National nosocomial infections surveillance system (NNIS): Description of surveillance methods

The National Nosocomial Infections Surveillance System (NNIS) is an ongoing collaborative surveillance system sponsored by the Centers for Disease Control (CDC) to obtain national data on nosocomial infections. The CDC uses the data that are reported voluntarily by participating hospitals to estimate the magnitude of the nosocomial infection problem in the United States and to monitor trends in infections and risk factors. Hospitals collect data by prospectively monitoring specific groups of patients for infections with the use of protocols called surveillance components. The surveillance components used by the NNIS are hospitalwide, intensive care unit, high-risk nursery, and surgical patient. Detailed information including demographic characteristics, infections and related risk factors, pathogens and their antimicrobial susceptibilities, and outcome, is collected on each infected patient. Data on risk factors in the population of patients being monitored are also collected; these permit the calculation of risk-specific rates. An infection risk index, which includes the traditional wound class, is being evaluated as a predictor of the likelihood that an infection will develop after an operation. A major goal of the NNIS is to use surveillance data to develop and evaluate strategies to prevent and control nosocomial infections. The data collected with the use of the surveillance components permit the calculation of risk-specific infection rates, which can be used by individual hospitals as well as national health-care planners to set priorities for their infection control programs and to evaluate the effectiveness of their efforts. The NNIS will continue to evolve in finding more effective and efficient ways to assess the influence of patient risk and changes in the financing of health care on the infection rate.

Pseudomonas cepacia colonization in patients with cystic fibrosis: Risk factors and clinical outcome†

During the period of 1979 to 1983, 38 patients with cystic fibrosis (CF) at the CF center of St. Christophers Hospital for Children in Pennsylvania developed respiratory tract colonization with Pseudomonas cepacia. Seventeen (45%) of the patients with colonization died. Yearly incidence rates of P. cepacia colonization fluctuated between 1.3% and 6.1%, suggesting an endemic phenomenon. Case-control studies showed that severe underlying CF, use of aminoglycosides, and having a sibling with CF and P. cepacia colonization were significant risk factors for P. cepacia colonization. Once colonized with P. cepacia, patients with CF were likely to be hospitalized longer (P = 0.008) and to die sooner (P = 0.0001) than control patients with CF. Environmental and microbiologic studies did not identify a common source or mode of transmission of P. cepacia among patients. The results of this investigation suggest that P. cepacia colonization of patients with CF was endemic in the hospital, occurred more frequently in those with severe disease, and was associated with adverse clinical outcome.

Update from the SENIC project: Hospital infection control: Recent progress and opportunities under prospective payment

From a survey of all U.S. hospitals in 1976 and of a random sample in 1983, we found that the intensity of infection surveillance and control activities greatly increased, and the percentage of hospitals with an infection control nurse per 250 beds increased from 22% to 57%. The percentage with a physician trained in infection control remained low (15%), and there was a drop in the percentages of hospitals doing surgical wound infection surveillance (from 90% down to 79%) and reporting surgeon-specific rates to surgeons (from 19% down to 13%). There was an increase in the percentage of hospitals with programs shown to be effective in preventing urinary tract infections, bacteremias, and pneumonias, but not surgical wound infections. The percentage of nosocomial infections being prevented nationwide appears to have increased from 6% to only 9%, whereas 32% could be prevented if all hospitals adopted the most effective programs.

Experience with Seed Localization for Nonpalpable Breast Lesions in a Public Health Care System

BackgroundSeed localization uses a radioactive source to identify nonpalpable breast lesions for excision; it is an emerging alternative to wire localization (WL). Previous single health system studies report decreased rates of re-excision and improved patient convenience with this technique. This study is the first to implement this procedure in a public health care delivery system composed of a primarily minority and low-income population.Materials and MethodsA multidisciplinary team was formed to create a protocol for breast seed localization (BSL) and monitor the results. After 50 seed localizations were successfully completed, a retrospective matched-pair analysis with patients who had undergone WL during the same period was performed.ResultsOverall experience with the BSL protocol is reviewed, along with the occurrence of a seed loss. Processes necessary to reactivate the BSL protocol and prevent future losses are delineated. BSL is associated with decreased rates of re-excision and can be successfully implemented in a public health care system.ConclusionsBSL is an attractive alternative to WL in a high-volume, county-based population. It allows increased efficiency in the operating room and has a low rate of complications. Cautionary measures must be taken to ensure proper seed chain of custody to prevent seed loss.

Family history of convulsions and use of pertussis vaccine

To evaluate the risk of neurologic events after vaccination with diphtheria-tetanus-pertussis (DTP) vaccine, we used data from the Centers for Disease Control Monitoring System for Adverse Events Following Immunization to compare the family history of convulsions in persons reporting neurologic events with that in persons reporting nonneurologic events; these events have an onset within 3 days of immunization with DTP vaccine, given either alone or with oral poliovirus vaccine. Persons reporting neurologic events were 6.4 times more likely to report a prior personal history of convulsions than those reporting nonneurologic events (95% confidence interval 4.7 to 8.8), and were 2.4 times more likely to report a history of convulsions in first-degree family members, that is, siblings or parents (95% confidence interval 1.7 to 3.4). Similar risks were noted for subgroup analyses controlling for type of event (febrile vs nonfebrile convulsion), age at immunization, source of report, number of previous doses of DTP vaccine, and day of onset. Because the Centers for Disease Control monitoring system receives reports on a nonrandom sample of all adverse events after immunization, selection bias could not be ruled out. On the basis of these data, we conclude that children with a family history of seizures are at increased risk of neurologic events, primarily febrile convulsions, after DTP vaccination. However, this increase in risk may reflect a nonspecific familial tendency for convulsions rather than a specific vaccine effect. Considering the rare occurrence of neurologic events after DTP vaccination, the generally benign outcome of febrile convulsions (which make up the majority of these neurologic events), and the possible increased risk of pertussis in the general population if the estimated 5% to 7% of persons with a first-degree family history of convulsions were exempted from pertussis vaccination, we further conclude that a history of convulsions in siblings or parents should not be a contraindication to pertussis vaccination. Special care in the prevention of postvaccination fever may be warranted in children with a family history of seizures.

565 UNUSUAL SYNDROME IN PREMATURE INFANTS ASSOCIATED WITH INTRAVENOUS E-FEROL

Three clusters of an unusual syndrome In premature infants in 3 intensive care nurseries were investigated. A case (C) was defined as an infant who developed ascites or at least 2 of the following in a 7-day period: serum direct bilirubin >2 mg/dl, blood urea nitrogen >40 mg/dl or serum creatinine >2 mg/dl, and platelet count <60,000/mm3. Of 68 babies weighing < 1250 gm at birth and surviving beyond 72h, 17 cases occurred with 13 deaths. All cases occurred after the introduction and use of intravenous E-Ferol (EF). 17 of 17 (100%) C but only 23 of 51 (41%) noncase (NC) babies had received EF (p<.001). C and NC infants were similar with respect to other complications, medications, and parenteral nutrition. Significant differences between C and NC babies who received EF (EF NC) are shown as mean ± SE:EF therapy duration was similar among C and EF NC babies. A dose-response relationship was found with C occurring at EF doses exceeding 20 U/kg/day. Liver, kidney, and intestine routine histology from autopsied C had no uniformly specific abnormalities. No new C were reported after EF use was stopped in the nurseries.